RBOT vs. SMTI, INGN, LAKE, ZJYL, MLSS, APT, SPAI, NTRB, CLGN, and COCH
Should you be buying Vicarious Surgical stock or one of its competitors? The main competitors of Vicarious Surgical include Sanara MedTech (SMTI), Inogen (INGN), Lakeland Industries (LAKE), Jin Medical International (ZJYL), Milestone Scientific (MLSS), Alpha Pro Tech (APT), Safe Pro Group Inc. Common Stock (SPAI), Nutriband (NTRB), CollPlant Biotechnologies (CLGN), and Envoy Medical (COCH). These companies are all part of the "surgical appliances & supplies" industry.
Vicarious Surgical vs.
Vicarious Surgical (NYSE:RBOT) and Sanara MedTech (NASDAQ:SMTI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, community ranking, valuation, media sentiment, profitability and risk.
Sanara MedTech has higher revenue and earnings than Vicarious Surgical. Sanara MedTech is trading at a lower price-to-earnings ratio than Vicarious Surgical, indicating that it is currently the more affordable of the two stocks.
47.3% of Vicarious Surgical shares are held by institutional investors. Comparatively, 8.1% of Sanara MedTech shares are held by institutional investors. 11.7% of Vicarious Surgical shares are held by insiders. Comparatively, 54.1% of Sanara MedTech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Sanara MedTech received 11 more outperform votes than Vicarious Surgical when rated by MarketBeat users. Likewise, 55.88% of users gave Sanara MedTech an outperform vote while only 33.33% of users gave Vicarious Surgical an outperform vote.
Vicarious Surgical has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Sanara MedTech has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.
In the previous week, Sanara MedTech had 4 more articles in the media than Vicarious Surgical. MarketBeat recorded 6 mentions for Sanara MedTech and 2 mentions for Vicarious Surgical. Sanara MedTech's average media sentiment score of 0.56 beat Vicarious Surgical's score of 0.00 indicating that Sanara MedTech is being referred to more favorably in the news media.
Vicarious Surgical currently has a consensus price target of $10.25, indicating a potential downside of 27.24%. Sanara MedTech has a consensus price target of $47.00, indicating a potential upside of 38.24%. Given Sanara MedTech's stronger consensus rating and higher probable upside, analysts plainly believe Sanara MedTech is more favorable than Vicarious Surgical.
Vicarious Surgical has a net margin of 0.00% compared to Sanara MedTech's net margin of -10.71%. Sanara MedTech's return on equity of -19.86% beat Vicarious Surgical's return on equity.
Summary
Sanara MedTech beats Vicarious Surgical on 14 of the 17 factors compared between the two stocks.
Get Vicarious Surgical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RBOT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vicarious Surgical Competitors List
Related Companies and Tools
This page (NYSE:RBOT) was last updated on 1/21/2025 by MarketBeat.com Staff
